Arix Bioscience
Arix Bioscience, a leading life sciences company headquartered in Great Britain, focuses on advancing innovative therapies in the biotechnology sector. Founded in 2013, Arix has established itself as a key player in the industry, with a strong presence in Europe and North America. The company is dedicated to identifying and developing breakthrough treatments across various therapeutic areas, including oncology and rare diseases. Arix Bioscience is renowned for its unique approach to investment and collaboration, fostering the growth of early-stage companies with transformative potential. With a robust portfolio of core products and services, Arix is committed to addressing unmet medical needs and enhancing patient outcomes. The company’s strategic partnerships and notable achievements position it as a prominent force in the life sciences landscape, driving innovation and delivering value to stakeholders.
DitchCarbon Score
How does Arix Bioscience's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Arix Bioscience's score of 27 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Arix Bioscience's reported carbon emissions
Arix Bioscience, headquartered in Great Britain, reported a total carbon emissions figure of approximately 8,890 tonnes CO2e for the year 2022. This figure includes about 3,680 tonnes CO2e from Scope 1 emissions and approximately 4,410 tonnes CO2e from Scope 2 emissions, with a market-based approach accounting for the entirety of Scope 2 emissions. In 2021, the company recorded total emissions of about 8,890 tonnes CO2e globally, with Scope 1 emissions at approximately 4,860 tonnes CO2e and Scope 2 emissions at around 7,530 tonnes CO2e (location-based). The 2020 emissions data showed a significant reduction, with total emissions of about 5,110 tonnes CO2e, primarily from Scope 1 (about 5,020 tonnes CO2e) and Scope 2 (approximately 6,770 tonnes CO2e). Despite these reductions, Arix Bioscience has not publicly committed to specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or climate pledges. The company continues to monitor its emissions and is likely to align with industry standards for climate action in the future.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2017 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|
| Scope 1 | 14,100 | 0,000 | 0,000 | 0,000 |
| Scope 2 | 7,000 | 0,000 | 0,000 | 0,000 |
| Scope 3 | - | 00 | 0,000 | 0,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Arix Bioscience is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
